Stocks Health care SBFM
NASDAQ · Health careSunshine Biopharma Inc. (SBFM)
Sunshine Biopharma Inc. brought in $35.3M of revenue over the twelve months to June 30, 2026, down 2.7% from a year earlier. It posted a net loss of $5.8M. In fiscal 2025 capital spending exceeded operating cash flow by $5.5M. At June 30, 2026 it held $13.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Watch SBFM in 60 secondsWhat Sunshine Biopharma Inc. does
Sunshine Biopharma Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SBFM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $36.3M | -$6M | -$1.44 | -$5.5M |
| 2024 | $34.9M | -$5.1M | -$7.32 | -$14.2M |
| 2023 | $24.1M | -$4.5M | -$351.36 | -$8.9M |
| 2022 | $4.3M | -$26.7M | -$3,254.70 | -$5.4M |
| 2021 | $228.4K | -$12.4M | -$8,802.49 | -$1.8M |
| 2020 | $71.4K | -$2.8M | -$5,048.49 | -$658.5K |
Full financial statements: income, balance sheet and cash flow
Where SBFM ranks in Health care
Latest SEC filings
What Sunshine Biopharma Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 16, 2026Form PRE 14C filing PRE 14C
- September 16, 2026
- September 11, 2026Other event 8-K
- September 8, 2026
- August 28, 2026IPO registration S-1
- August 28, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 1.6% to $9.3M versus the same quarter last year; diluted EPS -$1.15 versus -$0.82.
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 3, 2026Other event 8-K
Insider trades
What the people running Sunshine Biopharma Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 7, 2026 | Natan DavidDirector | Received as pay | 58,300 | - |
Who owns SBFM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Mitchell P. Kopin13G, passive with 2 related filers | 9.99% | August 13, 2026 |
| Bigger Michael13G, passive with 6 related filers | 9.47% | May 21, 2026 |
| Alta Partners LLC13G, passive | 8.6% | July 8, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 68,300 shares in total, about $57.5K at the last price.
| Holder | Shares |
|---|---|
| Natan DavidDirector | 68,300 |
Questions about SBFM
What does Sunshine Biopharma Inc. do?
Sunshine Biopharma Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SBFM.
Is Sunshine Biopharma Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $5.8M on revenue of $35.3M.
How much revenue does Sunshine Biopharma Inc. make?
Over the twelve months to June 30, 2026 Sunshine Biopharma Inc. reported revenue of $35.3M. That is 2.7% less than a year earlier.
When did Sunshine Biopharma Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the form PRE 14C filing from September 16, 2026.
Similar companies
Compare SBFM with
Follow SBFM
Get an email when Sunshine Biopharma Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow SBFM: get an email when it filesWhere the numbers come from
Financial figures are the values Sunshine Biopharma Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.